Immunotherapy
Cancer treatment that trains the patient's own immune system to attack tumors.
Coverage of Immunotherapy is holding steady : 13 signals on the latest tracked day, down 24% from its three-week baseline of 17, across 5 domains (up from 4 a week ago). That makes it the #30 most-covered of the 348 concerns we track.
What’s changed
- Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients. · J Immunother Cancer · 2026-09-02
- Cancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy. · Clin Transl Med · 2026-09-01
- Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status · Clinical Colorectal Cancer · 2026-08-31
- Pan-cancer single-cell atlas of immunotherapy response identifies ZNF385A as a regulator of immune evasion in small cell lung cancer. · Biochim Biophys Acta Mol Basis Dis · 2026-08-29
- A Case of POLE-Mutated, dMMR/MSI Colorectal Cancer With an Exceptional Response to Immunotherapy. · Am J Ther · 2026-08-26
- Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy. · Eur J Med Chem · 2026-08-25
What the reporting says
It shows up alongside Colorectal Cancer (208), MSI-H (46), Lung Cancer (39), Icis (22), KRAS (22), Braf (18), Egfr (18), Chen (18).
Two steps out: ctDNA (through Colorectal Cancer, 107 shared stories on the weaker link); Wang (through Colorectal Cancer, 59 shared stories on the weaker link); Zhang (through Colorectal Cancer, 50 shared stories on the weaker link); Systematic Review (through Colorectal Cancer, 46 shared stories on the weaker link).
Tracked since Dec 31, with coverage on 112 separate days — concentrated in Oncology and Pubmed Targeted.